title: IMPACT OF VITREORETINAL INTERFACE ARCHITECTURE ON SUCCESSFUL VITREOMACULAR TRACTION RESOLUTION IN EYES SCHEDULED FOR INTRAVITREAL OCRIPLASMIN THERAPY.
abstract: OBJECTIVE
  To evaluate the impact of the vitreoretinal interface architecture, in specific the angle between the posterior vitreous cortex and the internal limiting membrane, on vitreomacular traction (VMT) resolution in eyes treated with intravitreally injected ocriplasmin (Jetrea).
  
  
  METHODS
  Retrospective, multicenter cohort study and exploratory data analysis. Spectral domain optical coherence tomography assessments were performed before scheduled ocriplasmin injections. General (age and sex) as well as ocular variables (lens status, presence of epiretinal membrane formations, horizontal diameter of VMT, central retinal thickness, and in particular various prespecified angles between the posterior vitreous cortex and internal limiting membrane) were analyzed to evaluate their impact on successful VMT resolution.
  
  
  RESULTS
  Fifty-nine eyes of 59 patients were included. Univariate analysis of age (odds ratio [OR]: 0.881; 95% CI: [0.812-0.955]; P = 0.0022) and lens status (OR: 11.03; 95% CI: [2.23-54.57]; P = 0.0033) had a significant impact on successful VMT resolution, whereas sex (OR: 0.668; 95% CI: [0.126-2.065]; P = 0.4906), epiretinal membrane formation (OR: 0.581; 95% CI: [0.168-2.006]; P = 0.3903), horizontal diameter of VMT (OR: 0.99930; 95% CI: [0.99825-1.00035]; P = 0.1886), and central retinal thickness (OR: 0.9985; 95% CI: [0.9934-1.00436]; P = 0.56) failed. The angle at 500 μm apart from the fovea centralis, irrespective if measured nasally (OR: 1.135; 95% CI: [1.013-1.272]; P = 0.0289) or temporally (OR: 1.099; 95% CI: [1.001-1.208]; P = 0.0485), showed a significant correlation with VMT resolution.
  
  
  CONCLUSIONS
  The angle between the posterior vitreous cortex and the internal limiting membrane 500 μm apart from the fovea centralis correlates with VMT resolution and may be a clinically useful marker for selection of patients to be treated with ocriplasmin. This observation needs to be proven in a prospective confirmatory investigation.
authors: *Department of Ophthalmology, Philipps-University Marburg, Germany; †Institute of Medical Biometry and Epidemiology, Philipps-University Marburg, Marburg, Germany; ‡Department of Ophthalmology, University of Cologne, Cologne, Germany; §Internationale Innovative Ophthalmochirurgie (IIO), Düsseldorf, Germany; ¶Department of Ophthalmology, Knappschaftskrankenhaus Sulzbach, Sulzbach, Germany; **Department of Ophthalmology, Feldkirch State Hospital, Feldkirch, Austria; ††Department of Ophthalmology, Pallas Clinic, Aarau, Switzerland; ‡‡Department of Ophthalmology, Rheinische Friedrich-Wilhelms-University, Bonn, Germany; §§Department of Ophthalmology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany; and ¶¶Department of Ophthalmology, University Medical Center Goettingen, Goettingen, Germany.
authors: Christoph
authors: C
authors: Paul
authors: Christine
authors: C
authors: Heun
authors: Hans H
authors: HH
authors: Müller
authors: Sascha
authors: S
authors: Fauser
authors: Hakan
authors: H
authors: Kaymak
authors: Sara
authors: S
authors: Kazerounian
authors: Walter
authors: W
authors: Sekundo
authors: Stefan
authors: S
authors: Mennel
authors: Carsten H
authors: CH
authors: Meyer
authors: Steffen
authors: S
authors: Schmitz-Valckenberg
authors: Michael J
authors: MJ
authors: Koss
authors: Nicolas
authors: N
authors: Feltgen
authors: Thomas
authors: T
authors: Bertelmann
mesh_terms: D000368:Aged; D005260:Female; D005341:Fibrinolysin / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage*; D012160:Retina / Q000473:pathology*; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies; D013997:Time Factors; D041623:Tomography, Optical Coherence / Q000379:methods*; D016896:Treatment Outcome; D014792:Visual Acuity; D014822:Vitreous Body / Q000473:pathology*
chemical_list: D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin